EBViNT, which targets Epstein–Barr virus (EBV)-positive cancers, is in phase 2 for the treatment of natural killer/T cell (NK/T cell ... rather than CD1 9, which is expressed also on healthy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback